利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1148 条记录 (耗时 0.033 秒)

    Composition and methods for relief of chemical sensitivity
    51.
    发明授权
    Composition and methods for relief of chemical sensitivity 有权
    缓解化学敏感性的组成和方法

    公开(公告)号：US08932645B2

    公开(公告)日：2015-01-13

    申请号：US14320958

    申请日：2014-07-01

    申请人： Jeffrey Comanor

    发明人： Jeffrey Comanor

    IPC分类号： A61K31/40 ,  A61K31/28 ,  A61K31/122 ,  A61K33/42 ,  A61K31/201 ,  A61K31/519

    CPC分类号： A61K31/28 ,  A61K31/047 ,  A61K31/122 ,  A61K31/19 ,  A61K31/194 ,  A61K31/201 ,  A61K31/205 ,  A61K31/519 ,  A61K31/525 ,  A61K31/7004 ,  A61K33/24 ,  A61K33/42 ,  A61K2300/00

    摘要： The formulations of the present disclosure alter the perception of symptoms, especially as experienced by subjects reporting the characteristic features associated with the syndrome known as multiple chemical sensitivity (MCS). The present disclosure encompasses formulations for the relief of symptoms associated with MCS, where the formulations comprise orthophosphoric acid, a vegetable oil comprising an esterified mono-unsaturated fatty acid, folic acid, and a molybdenum salt. The formulations can further comprise magnesium citrate, magnesium aspartate, malic acid, L-carnitine, alpha-ketoglutaric acid, co-enzyme Q10, glycerol, inositol, and choline bitartrate, optionally Q10, and riboflavin to provide a yellow color to the formulation. Another aspect of the disclosure are methods for alleviating MCS-related symptoms in subject human, comprising: providing to a subject an effective dose of a formulation comprising orthophosphoric acid, a mono-unsaturated fat, folic acid, molybdenum, and water.

    摘要翻译： 本公开的制剂改变症状的感觉，特别是由报道与称为多重化学敏感性（MCS）的综合征的特征相关的受试者所经历的症状。 本公开内容包括用于缓解与MCS相关的症状的制剂，其中制剂包含正磷酸，包含酯化单不饱和脂肪酸，叶酸和钼盐的植物油。 制剂还可以包含柠檬酸镁，天冬氨酸镁，苹果酸，L-肉毒碱，α-酮戊二酸，辅酶Q10，甘油，肌醇和酒石酸胆碱，任选的Q10和核黄素，以向制剂提供黄色。 本公开的另一方面是减轻受试者的MCS相关症状的方法，其包括：向受试者提供有效剂量的包含正磷酸，单不饱和脂肪，叶酸，钼和水的制剂。

    TREATMENT OF HYPOTENSION ASSOCIATED WITH HEMODIALYSIS
    52.
    发明申请
    TREATMENT OF HYPOTENSION ASSOCIATED WITH HEMODIALYSIS 审中-公开
    治疗与HEMODIALYSIS相关的HYPTEIONION

    公开(公告)号：US20140350097A1

    公开(公告)日：2014-11-27

    申请号：US13901323

    申请日：2013-05-23

    申请人： Medinox,Inc.

    发明人： Ching-San Lai

    IPC分类号： A61K31/27 ,  G01N33/50 ,  A61K31/165

    CPC分类号： A61K31/27 ,  A61K31/165 ,  A61K31/28 ,  A61K33/26 ,  G01N33/50 ,  G01N33/84 ,  G01N2333/90254 ,  G01N2800/52 ,  Y10T436/173076 ,  Y10T436/177692 ,  A61K2300/00

    摘要： There is provided a method for the prevention and/or treatment of hypotension associated with hemodialysis, which method includes administering to a subject in need thereof an effective amount of at least one physiologically compatible compound which, in combination with iron, binds nitric oxide. There is further provided a method for identifying hemodialysis subjects for whom treatment with an effective amount of at least one physiologically compatible compound which, in combination with iron, binds nitric oxide is indicated. The method includes monitoring the subject's nitric oxide levels, and selecting those subjects having elevated nitric oxide levels for treatment with an effective amount of at least one physiologically compatible compound which, in combination with iron, binds nitric oxide, wherein the effective amount is sufficient to maintain the subject's nitric oxide levels within an acceptable range.

    摘要翻译： 提供了用于预防和/或治疗与血液透析相关的低血压的方法，该方法包括向有需要的受试者施用有效量的与铁结合的至少一种生理上相容的化合物结合一氧化氮。 还提供了一种用于鉴定血液透析受试者的方法，用有效量的至少一种与铁结合一氧化氮的生理相容性化合物进行治疗。 该方法包括监测受试者的一氧化氮水平，并选择具有升高的一氧化氮水平的受试者用有效量的至少一种生理上相容的化合物进行治疗，所述化合物与铁结合一氧化氮，其中有效量足以 将受试者的一氧化氮水平维持在可接受的范围内。

    COMPOSITION AND METHODS FOR RELIEF OF CHEMICAL SENSITIVITY
    53.
    发明申请
    COMPOSITION AND METHODS FOR RELIEF OF CHEMICAL SENSITIVITY 有权
    化学敏感性的组合物和方法

    公开(公告)号：US20140314730A1

    公开(公告)日：2014-10-23

    申请号：US14320958

    申请日：2014-07-01

    申请人： Jeffrey Comanor

    发明人： Jeffrey Comanor

    IPC分类号： A61K31/28 ,  A61K31/519 ,  A61K31/201 ,  A61K31/122 ,  A61K33/42

    CPC分类号： A61K31/28 ,  A61K31/047 ,  A61K31/122 ,  A61K31/19 ,  A61K31/194 ,  A61K31/201 ,  A61K31/205 ,  A61K31/519 ,  A61K31/525 ,  A61K31/7004 ,  A61K33/24 ,  A61K33/42 ,  A61K2300/00

    摘要： The formulations of the present disclosure alter the perception of symptoms, especially as experienced by subjects reporting the characteristic features associated with the syndrome known as multiple chemical sensitivity (MCS). The present disclosure encompasses formulations for the relief of symptoms associated with MCS, where the formulations comprise orthophosphoric acid, a vegetable oil comprising an esterified mono-unsaturated fatty acid, folic acid, and a molybdenum salt. The formulations can further comprise magnesium citrate, magnesium aspartate, malic acid, L-carnitine, alpha-ketoglutaric acid, co-enzyme Q10, glycerol, inositol, and choline bitartrate, optionally Q10, and riboflavin to provide a yellow color to the formulation. Another aspect of the disclosure are methods for alleviating MCS-related symptoms in subject human, comprising: providing to a subject an effective dose of a formulation comprising orthophosphoric acid, a mono-unsaturated fat, folic acid, molybdenum, and water.

    摘要翻译： 本公开的制剂改变症状的感觉，特别是由报道与称为多重化学敏感性（MCS）的综合征的特征相关的受试者所经历的症状。 本公开内容包括用于缓解与MCS相关的症状的制剂，其中制剂包含正磷酸，包含酯化单不饱和脂肪酸，叶酸和钼盐的植物油。 制剂还可以包含柠檬酸镁，天冬氨酸镁，苹果酸，L-肉毒碱，α-酮戊二酸，辅酶Q10，甘油，肌醇和酒石酸胆碱，任选的Q10和核黄素，以向制剂提供黄色。 本公开的另一方面是减轻受试者的MCS相关症状的方法，其包括：向受试者提供有效剂量的包含正磷酸，单不饱和脂肪，叶酸，钼和水的制剂。

    NEW USE OF L-HISTIDINE AND DERIVATIVES THEREOF
    56.
    发明申请
    NEW USE OF L-HISTIDINE AND DERIVATIVES THEREOF 有权
    其新的使用方法及其衍生物

    公开(公告)号：US20140155449A1

    公开(公告)日：2014-06-05

    申请号：US14235128

    申请日：2012-07-24

    申请人： Baranyai Zsolt ,  Ernö Brücher ,  Simona Bussi ,  Alessandro Maiocchi ,  Fulvio Uggeri

    发明人： Baranyai Zsolt ,  Ernö Brücher ,  Simona Bussi ,  Alessandro Maiocchi ,  Fulvio Uggeri

    IPC分类号： A61K31/4172 ,  A61K31/28

    CPC分类号： A61K31/4172 ,  A61K31/28

    摘要： The present invention discloses the use of L-Histidine to reduce Gadolinium accumulation into target organs, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the use of L-Histidine to prevent the NSF syndrome in patients with renal functionality impairment. A kit of part is also disclosed by the use of which toxicity associated to free Gd3+, deriving from GDBCA, is prevented by oral administration of L-histidine before administration of the contrast agent. A method for the prevention of toxic metal accumulation which consists in the administration, preferably by the oral route, of L-Histidine is also disclosed. L-Histidine is preferably administered a s a single oral dose comprised from 0.2-20 g.

    摘要翻译： 本发明公开了在施用钆基造影剂之后，L-组氨酸用于减少钆累积到靶器官中，防止其毒性作用。 因此，本发明还公开了使用L-组氨酸来预防肾功能损害患者的NSF综合征。 还通过使用与给予造影剂之前通过口服给予L-组氨酸来防止与GDBCA相关的游离Gd3 +相关毒性的试剂盒。 还公开了一种用于预防毒性金属积聚的方法，该方法包括优选通过口服途径施用L-组氨酸。 L-组氨酸优选以0.2-20g的单一口服剂量施用。